Stockscreener 앱 받기
1.39
1.46%
0.02
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
Rodman & Renshaw initiates Telomir Pharma stock with Buy rating By Investing.com - Investing.com Canada
Aug Shorts: Is ImmuCell Corporation forming a bullish divergenceEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Received Notice of Noncompliance - TradingView — Track All Markets
Is Telomir Pharmaceuticals Inc. stock a top momentum playJuly 2025 Summary & Growth Focused Entry Point Reports - Улправда
Published on: 2026-01-10 12:17:57 - Улправда
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Movers: Why Telomir Pharmaceuticals Inc. stock is recommended by analystsGlobal Markets & Real-Time Market Trend Scan - Улправда
Is Telomir Pharmaceuticals Inc. stock in correction or buying zoneJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - Улправда
Why retail investors favor Telomir Pharmaceuticals Inc. stockQuarterly Portfolio Summary & AI Forecast for Swing Trade Picks - Улправда
Trend Review: Why retail investors favor Telomir Pharmaceuticals Inc stockEarnings Growth Report & Step-by-Step Trade Execution Guides - Bộ Nội Vụ
Can Telomir Pharmaceuticals Inc. stock sustain revenue growthMerger & Acquisition Updates & Build Wealth With Expert Timing Advice - Улправда
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models - The Florida Times-Union
How Telomir Pharmaceuticals Inc. stock reacts to inflationary pressuresLow Risk Investment Ideas & Minimal Investment Portfolio Growth - ulpravda.ru
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models - Investing.com Australia
Coinbase CEO Brian Armstrong Says His Biotech Company Is Working On 'Extending' Human Lifespan: Here Is How They Plan To Do It - Benzinga
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC - TipRanks
Telomir Pharmaceuticals Reports Positive Preclinical Results for Telomir-1 - TradingView — Track All Markets
Experimental breast cancer drug slows aggressive tumors in animal tests - Stock Titan
Is Telomir Pharmaceuticals Inc. stock positioned for digital transformationOptions Trading Strategies & Start Investing With Free Smart Watchlists - bollywoodhelpline.com
Telomir Pharmaceuticals reports preclinical results for Telomir-1 in TNBC models By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Lancaster Eagle-Gazette
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened - Defense World
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9%Here's What Happened - MarketBeat
Is Telomir Pharmaceuticals Inc stock oversold or undervaluedRisk Management & Weekly Hot Stock Watchlists - moha.gov.vn
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Momentum Shift: What is the fair value of Telomir Pharmaceuticals Inc stock nowPortfolio Profit Report & AI Driven Stock Movement Reports - Bộ Nội Vụ
Telomir Pharmaceuticals sets CEO incentive awards and salary adjustment - Investing.com
4.73%
0.92%
자본화:
|
볼륨(24시간):